BioStem Technologies, Inc. (BSEM)
Nasdaq · Healthcare · Biotechnology
$2.76+0.92%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $51.4M
- P/E (trailing)
- 3.1
- Forward P/E
- 9.5
- 52-week range
- $2.25 – $8.40
- 52-week change
- −42.89%
- EPS (trailing)
- $0.88
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $47.5M (−31.84%)
- Net income
- −$6.6M
- Operating margin
- −1.5%
- Diluted EPS
- −$0.39
- Free cash flow
- $6.6M
From the company’s annual report on SEC EDGAR.
About BioStem Technologies, Inc.
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Headquarters: Fort Lauderdale, United States · 73 employees · biostemtechnologies.com